Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 14,150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: COPD
Interventions: Perforomist-Placebo, Perforomist, nebulization, COPD; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Healthy Volunteers
Interventions: NasoShield, BioThrax, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Melbourne, Florida • San Antonio, Texas

Conditions: Ocular Infection
Interventions: DCN01, Unisol; Drug
Lead sponsor: Deacon Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy Adults
Interventions: Follistatin and klotho gene therapy; Genetic
Lead sponsor: Minicircle; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Pain Management
Interventions: MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Chronic Pruritus, Atopic Dermatitis
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 28
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Cytomegalovirus Infection
Interventions: Brincidofovir, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more

Conditions: Agitation, Schizophrenia
Interventions: Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Epoetin Alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 89
States / cities: Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more

Conditions: Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions: ALD-401, Sham Procedure; Biological · Procedure
Lead sponsor: Aldagen; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more

Conditions: Healthy Volunteers
Interventions: E2511, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy, Rheumatoid Arthritis
Interventions: IA-14069, Placebo, Methotrexate; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Neridronic acid 100 mg, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more

Conditions: Healthy
Interventions: PF-04958242, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: ADHD
Interventions: Placebo, 400mg SPN-812, 600mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more

Conditions: Acute Coronary Syndrome
Interventions: Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 49
States / cities: Alexander City, Alabama • Banning, California • Sylmar, California + 46 more

Conditions: Healthy
Interventions: CAY001, Placebo; Drug · Other
Lead sponsor: Cayuga Biotech, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Work-related Injury
Interventions: individual -Brief Motivational Intervention (BMI), Group (Group Problem Solving), Standard of Care (OSHA 10 Safety Cards); Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knee Osteoarthritis
Interventions: Lorecivivint, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 44
States / cities: Tucson, Arizona • Cerritos, California • La Mesa, California + 35 more

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Hypertension
Interventions: QUARTET LDQT, Candesartan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Bloomingdale, Illinois • Chicago, Illinois

Conditions: Plaque Psoriasis
Interventions: 188-0551 Solution, Vehicle Solution; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Search by objective public record fields.

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

NasoShield Study of Safety and Immunogenicity

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

Safety and Efficacy of Klotho and Follistatin Gene Therapy

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

MAD Study of IA-14069

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Study to Evaluate CAY001 in Healthy Volunteers

VALES+Tú: Targeting Psychosocial Stressors to Reduce Latino Day Laborers (LDL) Injury Disparities

Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)